NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

HALO

Halozyme Therapeutics Inc

May 20 • 03:02PM ET

53.34

Dollar change +0.04
Percentage change 0.08	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BIIB REGN AMGN GILD NBIX INCY ALNY EXEL IONS

| Held by: VTI IJH VB IWM VXF VBK XBI IWO XMHQ MDY

Scroll to Statements

Index	RUT	P/E	14.15	EPS (ttm)	3.77	Insider Own	1.10%	Shs Outstand	123.17M	Perf Week	6.18%
Market Cap	6.57B	Forward P/E	7.44	EPS next Y	7.16	Insider Trans	-3.33%	Shs Float	121.86M	Perf Month	-6.90%
Income	485.36M	PEG	0.49	EPS next Q	1.21	Inst Own	100.34%	Short Float	7.76%	Perf Quarter	-7.68%
Sales	1.08B	P/S	6.06	EPS this Y	26.57%	Inst Trans	0.56%	Short Ratio	4.46	Perf Half Y	-1.16%
Book/sh	3.92	P/B	13.62	EPS next Y	33.81%	ROA	24.04%	Short Interest	9.46M	Perf Year	17.50%
Cash/sh	6.07	P/C	8.79	EPS next 5Y	28.69%	ROE	147.06%	52W Range	42.01 - 70.50	Perf YTD	11.56%
Dividend Est.	-	P/FCF	13.26	EPS past 5Y	-	ROI	24.39%	52W High	-24.35%	Beta	1.15
Dividend TTM	-	Quick Ratio	7.30	Sales past 5Y	39.83%	Gross Margin	76.89%	52W Low	26.96%	ATR (14)	3.53
Dividend Ex-Date	-	Current Ratio	8.39	EPS Y/Y TTM	57.10%	Oper. Margin	55.10%	RSI (14)	42.02	Volatility	8.41% 5.24%
Employees	350	Debt/Eq	3.13	Sales Y/Y TTM	25.65%	Profit Margin	44.76%	Recom	2.33	Target Price	67.00
Option/Short	Yes / Yes	LT Debt/Eq	3.13	EPS Q/Q	56.46%	Payout	0.00%	Rel Volume	0.55	Prev Close	53.29
Sales Surprise	15.10%	EPS Surprise	20.18%	Sales Q/Q	35.22%	Earnings	May 06 AMC	Avg Volume	2.12M	Price	53.34
SMA20	-9.47%	SMA50	-11.87%	SMA200	-5.37%	Trades		Volume	1,003,789	Change	0.08%

Date	Action	Analyst	Rating Change	Price Target Change
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$62
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform	$47
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52
Jun-14-21	Initiated	Evercore ISI	Outperform
May-17-21	Initiated	SVB Leerink	Outperform	$56
May-11-21	Downgrade	Piper Sandler	Overweight → Neutral	$50 → $48
Jan-21-21	Reiterated	The Benchmark Company	Buy	$46 → $59
Dec-17-20	Initiated	Berenberg	Buy	$50

Show Previous Ratings

Today 11:50AM	CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies (Zacks)
09:11AM	REGN Signs $256M Buyout Deal With 23andMe to Boost Genomics Research (Zacks)
May-19-25 09:32AM	ACAD Stock Soars as US Court Rules in Favor of Key Nuplazid Patent (Zacks)
May-16-25 10:51AM	Incyte Gets FDA Approval for Zynyz in New Cancer Indication (Zacks) +6.27%
May-15-25 11:04AM	Kodiak Q1 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
05:41AM	Zacks.com featured highlights Sterling Infrastructure, AXIS Capital, Molina Healthcare and Halozyme (Zacks)
May-14-25 11:41AM	Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus (Zacks)
11:23AM	4 Stocks With Impressive Interest Coverage Ratio to Buy Now (Zacks)
11:00AM	Halozyme, J&J slide as analyst cuts rating on CMS draft guidance (TipRanks)
08:27AM	Why Halozyme Therapeutics, Inc. (HALO) Declined on Tuesday (Insider Monkey)
May-13-25 04:18PM	Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News (Investor's Business Daily) -24.56%
12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
09:45AM	Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy? (Zacks)
May-12-25 03:49PM	Is Halozyme Therapeutics (HALO) the Unstoppable Growth Stock to Invest in Now? (Insider Monkey)
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO) (Zacks)
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
May-10-25 11:47AM	S&P 500 Giants Visa, Insulet Lead 5 Stocks Near Buy Points (Investor's Business Daily)
May-09-25 12:00PM	Halozyme Therapeutics (HALO) is a Great Momentum Stock: Should You Buy? (Zacks)
10:36AM	Halozyme Therapeutics, Inc. (HALO): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
May-08-25 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
06:20AM	Should Invesco S&P MidCap 400 GARP ETF (GRPM) Be on Your Investing Radar? (Zacks)
01:47AM	Why Halozyme Therapeutics, Inc. (HALO) Skyrocketed On Wednesday (Insider Monkey)
May-07-25 12:13PM	HALO Stock Up on Q1 Earnings and Revenue Beat, Raised 2025 View (Zacks) +18.12%
03:19AM	Halozyme Therapeutics Inc (HALO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-06-25 07:00PM	Halozyme Therapeutics (HALO) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
05:35PM	Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
04:01PM	HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS (PR Newswire)
06:20AM	Is Invesco S&P MidCap 400 GARP ETF (GRPM) a Strong ETF Right Now? (Zacks)
May-05-25 05:15PM	Halozyme to Participate in the BofA Securities 2025 Healthcare Conference (PR Newswire)
May-01-25 09:06AM	Halozyme Therapeutics: Still Undervalued Ahead Of Earnings (Seeking Alpha)
Apr-30-25 10:01AM	Techne (TECH) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-29-25 10:01AM	Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy? (Zacks)
Apr-28-25 08:30AM	Halozyme to Report First Quarter 2025 Financial and Operating Results (PR Newswire)
07:30AM	Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection with ENHANZE for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PR Newswire)
Apr-25-25 06:34AM	Halozyme sues Merck; FDA blames cuts for Vanda delay (BioPharma Dive)
Apr-24-25 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:30AM	Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation (PR Newswire)
Apr-11-25 04:09PM	Biotech Stock Bounces From Support, Shows Relative Strength Amid Volatile Market (Investor's Business Daily)
Apr-10-25 06:15PM	Halozyme Announces FDA Approval of argenx's VYVGART Hytrulo Prefilled Syringe Co-Formulated with ENHANZE for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy (PR Newswire)
Apr-09-25 08:45AM	European Commission Approved Subcutaneous DARZALEX (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility (PR Newswire) +5.40%
Apr-08-25 09:40AM	Why This 1 Value Stock Could Be a Great Addition to Your Portfolio (Zacks)
Apr-07-25 09:29AM	European Commission Approves Subcutaneous RYBREVANT (amivantamab) Co-Formulated with ENHANZE for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer (PR Newswire)
Mar-31-25 08:30AM	Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo (nivolumab) with ENHANZE Across Multiple Solid Tumor Indications (PR Newswire)
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
02:50AM	abrdn Healthcare Investors Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 11:30AM	Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? (Zacks)
Mar-26-25 11:30AM	Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-24-25 01:56PM	Argenx: The Magic May Be Already Priced In (SeekingAlpha)
09:50AM	Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
Mar-21-25 10:10AM	Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
07:35AM	Halozyme Joins the $1 Billion Club (FX Empire)
Mar-13-25 12:39PM	Halozyme Stock Offers Early Buy Point As Company Hits $1 Billion In Revenue (Investor's Business Daily)
Mar-10-25 08:57AM	Artisan Small Cap Fund Reduced its Stake in Halozyme Therapeutics (HALO). Heres Why (Insider Monkey)
Mar-07-25 02:45PM	AutoZone Stock Can Hold Up Amid Tariffs, Analyst Says. Plus, Chewy, Chesapeake, and More. (Barrons.com)
Mar-05-25 02:42PM	New Version of Mercks Blockbuster Cancer Drug Threatened by Patent Battle (The Wall Street Journal)
09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)
Feb-26-25 08:30AM	Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference (PR Newswire)
Feb-24-25 12:45PM	Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes" (Zacks)
Feb-20-25 09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
Feb-19-25 07:10AM	Q4 2024 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:05AM	Halozyme Therapeutics Inc (HALO) Q4 2024 Earnings Call Highlights: Record Revenue and Strong ... (GuruFocus.com)
Feb-18-25 05:30PM	Halozyme Therapeutics (HALO) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Top Estimates (Zacks)
04:25PM	Halozyme Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:25PM	Recursion Pharmaceuticals Stock Scores RS Ratings Over 90 (Investor's Business Daily)
04:16PM	Incyte Stock Sees Relative Strength Rating Rise To 71 (Investor's Business Daily)
04:01PM	HALOZYME REPORTS FULL YEAR 2024 RECORD REVENUE OF $1.015 BILLION AND EXCEEDS ITS FINANCIAL GUIDANCE FOR ROYALTY REVENUE, ADJUSTED EBITDA AND NON-GAAP DILUTED EPS (PR Newswire)
Feb-13-25 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
Feb-12-25 06:13AM	Halozyme Therapeutics, Inc. (HALO): A Cheap Biotech Stock to Invest In Now (Insider Monkey)
Feb-06-25 08:00AM	Halozyme Stock Climbs Back After 2024 Sneak Peek As Earnings Loom (Investor's Business Daily)
Feb-04-25 08:30AM	Halozyme to Report Fourth Quarter and Full Year 2024 Financial and Operating Results (PR Newswire)
Feb-03-25 07:30AM	CHMP Issues Positive Opinion for Subcutaneous RYBREVANT(amivantamab) Co-Formulated with ENHANZE for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer (PR Newswire)
Jan-31-25 09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
Jan-28-25 09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
Jan-27-25 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
Jan-15-25 03:44PM	BeiGene Stock Meets 80-Plus RS Rating Benchmark (Investor's Business Daily)
Jan-14-25 03:30PM	BridgeBio Pharma Stock Earns 87 RS Rating (Investor's Business Daily)
Jan-10-25 12:45PM	Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why (Zacks)
Jan-09-25 08:52AM	Are Options Traders Betting on a Big Move in Halozyme (HALO) Stock? (Zacks)
Jan-08-25 02:54PM	SpringWorks Therapeutics Stock Gets A RS Rating Lift (Investor's Business Daily) +5.02%
07:43AM	Halozyme Preliminary 2024 Estimated Ranges Consistent With Guidance; Raises FY25 Guidance (RTT News)
07:00AM	Halozyme Reiterates 2024 Financial Guidance and Raises 2025 and Multi-Year Financial Guidance (PR Newswire)
Jan-06-25 08:30AM	Halozyme to Host Investor Conference Call to Provide Updated 2025 Financial Guidance (PR Newswire) +5.80%
Dec-30-24 07:00AM	Halozyme Announces Takeda Received Regulatory Approval for HYQVIA 10% Subcutaneous Injection Set with ENHANZE in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia (PR Newswire)
06:45AM	Halozyme Announces argenx's VYDURA with ENHANZE was Granted Regulatory Approval in Japan for Chronic Inflammatory Demyelinating Polyneuropathy (PR Newswire)
06:30AM	Halozyme Announces FDA Approval of Bristol Myers Squibb's Opdivo Qvantig with ENHANZE for Subcutaneous Use in Most Previously Approved Adult Solid Tumor Opdivo (nivolumab) Indications (PR Newswire)
Dec-23-24 12:45PM	3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO) (Zacks)
Dec-16-24 09:55AM	How Much Upside is Left in Halozyme Therapeutics (HALO)? Wall Street Analysts Think 27.08% (Zacks)
Dec-11-24 09:40AM	Halozyme Therapeutics (HALO) is a Top-Ranked Value Stock: Should You Buy? (Zacks)
Dec-09-24 09:45AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock (Zacks)
09:40AM	Is Halozyme Therapeutics (HALO) Stock Undervalued Right Now? (Zacks)
Dec-05-24 12:45PM	Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now (Zacks)
09:40AM	Is Halozyme Therapeutics (HALO) Outperforming Other Medical Stocks This Year? (Zacks)
Nov-27-24 08:30AM	Halozyme to Present at Upcoming Investor Conferences (PR Newswire)
Nov-22-24 12:12PM	Halozyme Withdraws Evotec Bid After Rebuff, Reaffirms Strong Growth Outlook (Benzinga) +7.22%
12:00PM	Halozyme Therapeutics (HALO) Upgraded to Buy: Here's Why (Zacks)
09:45AM	Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term (Zacks)
09:21AM	Halozyme shares jump 12% as it scraps $2.1 bln Evotec deal (Investing.com)
08:35AM	Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions (PR Newswire)
05:30AM	Halozyme drops Evotec buyout bid; Patient dies in Neurogene trial (BioPharma Dive)

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Henderson Jeffrey William	Director	Apr 28 '25	Sale	60.37	4,497	271,467	28,611	Apr 28 06:04 PM
Henderson Jeffrey William	Director	Apr 01 '25	Sale	64.05	503	32,217	33,108	Apr 01 06:32 PM
Henderson Jeffrey William	Director	Mar 03 '25	Sale	58.69	5,000	293,458	33,611	Mar 03 08:46 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 26 '25	Sale	58.12	10,000	581,244	175,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 25 '25	Sale	58.05	10,000	580,534	185,453	Feb 27 06:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 27 '25	Sale	58.28	1,697	98,902	173,756	Feb 27 06:32 PM
MICHAEL LABARRE	Officer	Feb 25 '25	Proposed Sale	58.50	21,697	1,269,274		Feb 25 04:32 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 23 '25	Option Exercise	0.00	4,747	0	197,863	Feb 24 05:11 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 23 '25	Option Exercise	0.00	7,012	0	32,264	Feb 24 05:07 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 23 '25	Option Exercise	0.00	6,688	0	35,501	Feb 24 05:04 PM
Torley Helen	PRESIDENT AND CEO	Feb 23 '25	Option Exercise	0.00	22,436	0	745,800	Feb 24 05:01 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 16 '25	Option Exercise	0.00	31,266	0	196,729	Feb 18 06:42 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Feb 15 '25	Option Exercise	0.00	3,386	0	177,142	Feb 18 06:42 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 16 '25	Option Exercise	0.00	22,205	0	32,411	Feb 18 06:41 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '25	Option Exercise	0.00	27,831	0	33,402	Feb 18 06:39 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 15 '25	Option Exercise	0.00	1,254	0	16,734	Feb 18 06:39 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '25	Option Exercise	0.00	109,694	0	744,548	Feb 18 06:37 PM
Torley Helen	PRESIDENT AND CEO	Feb 15 '25	Option Exercise	0.00	13,092	0	679,836	Feb 18 06:37 PM
Henderson Jeffrey William	Director	Feb 03 '25	Sale	56.30	5,000	281,517	38,611	Feb 04 06:07 PM
JEFFREY HENDERSON	Director	Feb 03 '25	Proposed Sale	56.64	15,000	849,600		Feb 03 04:21 PM
Henderson Jeffrey William	Director	Jan 06 '25	Sale	50.01	10,000	500,060	43,611	Jan 07 04:14 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jan 03 '25	Option Exercise	0.00	7,611	0	19,291	Jan 06 05:12 PM
JEFFREY HENDERSON	Director	Jan 06 '25	Proposed Sale	47.74	10,000	477,400		Jan 06 04:26 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Option Exercise	19.98	10,000	199,800	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Option Exercise	18.15	10,000	181,455	183,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 15 '24	Sale	53.75	10,000	537,469	173,756	Oct 16 06:53 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Oct 16 '24	Sale	53.26	10,000	532,590	173,756	Oct 16 06:53 PM
MICHAEL LABARRE	Officer	Oct 16 '24	Proposed Sale	53.26	10,000	532,592		Oct 16 04:14 PM
MICHAEL LABARRE	Officer	Oct 15 '24	Proposed Sale	53.75	10,000	537,466		Oct 15 04:34 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Option Exercise	13.87	10,000	138,700	686,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '24	Sale	54.00	10,000	539,961	676,744	Oct 09 05:39 PM
Torley Helen	PRESIDENT AND CEO	Oct 09 '24	Sale	52.58	10,000	525,783	676,744	Oct 09 05:39 PM
HELEN TORLEY	Officer	Oct 09 '24	Proposed Sale	52.58	10,000	525,778		Oct 09 04:09 PM
HELEN TORLEY	Officer	Oct 08 '24	Proposed Sale	54.00	10,000	539,956		Oct 08 04:08 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 24 '24	Sale	58.21	10,000	582,100	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 25 '24	Sale	56.34	10,000	563,370	676,744	Sep 26 06:06 PM
Torley Helen	PRESIDENT AND CEO	Sep 26 '24	Sale	56.10	10,000	560,970	676,744	Sep 26 06:06 PM
HELEN TORLEY	Officer	Sep 26 '24	Proposed Sale	56.10	10,000	560,970		Sep 26 04:05 PM
HELEN TORLEY	Officer	Sep 25 '24	Proposed Sale	56.34	10,000	563,368		Sep 25 04:00 PM
HELEN TORLEY	Officer	Sep 24 '24	Proposed Sale	58.21	10,000	582,101		Sep 24 04:05 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Option Exercise	16.65	10,000	166,500	183,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 17 '24	Sale	62.88	10,000	628,780	173,756	Sep 18 06:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Sep 18 '24	Sale	62.03	10,000	620,316	173,756	Sep 18 06:49 PM
MICHAEL LABARRE	Officer	Sep 18 '24	Proposed Sale	62.03	10,000	620,311		Sep 18 04:01 PM
MICHAEL LABARRE	Officer	Sep 17 '24	Proposed Sale	62.88	10,000	628,777		Sep 17 04:03 PM
Torley Helen	PRESIDENT AND CEO	Sep 10 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 12 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 11 '24	Option Exercise	13.87	10,000	138,700	686,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 12 '24	Sale	59.20	10,000	592,030	676,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 10 '24	Sale	59.09	10,000	590,890	676,744	Sep 12 05:56 PM
Torley Helen	PRESIDENT AND CEO	Sep 11 '24	Sale	59.09	10,000	590,870	676,744	Sep 12 05:56 PM
HELEN TORLEY	Officer	Sep 12 '24	Proposed Sale	59.20	10,000	592,028		Sep 12 04:12 PM
HELEN TORLEY	Officer	Sep 11 '24	Proposed Sale	59.09	10,000	590,873		Sep 11 04:05 PM
HELEN TORLEY	Officer	Sep 10 '24	Proposed Sale	59.09	10,000	590,897		Sep 10 04:16 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 27 '24	Option Exercise	18.41	5,580	102,728	173,756	Aug 27 07:49 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Option Exercise	16.65	10,000	166,500	178,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 21 '24	Sale	61.75	10,000	617,470	168,176	Aug 21 06:03 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Aug 20 '24	Sale	61.05	10,000	610,550	168,176	Aug 21 06:03 PM
MICHAEL LABARRE	Officer	Aug 21 '24	Proposed Sale	61.75	10,000	617,474		Aug 21 04:11 PM
MICHAEL LABARRE	Officer	Aug 20 '24	Proposed Sale	61.06	10,000	610,553		Aug 20 04:16 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Option Exercise	13.87	10,000	138,700	686,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 15 '24	Sale	57.95	10,000	579,490	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 14 '24	Sale	57.25	10,000	572,471	676,744	Aug 15 04:59 PM
Torley Helen	PRESIDENT AND CEO	Aug 13 '24	Sale	56.25	10,000	562,490	676,744	Aug 15 04:59 PM
HELEN TORLEY	Officer	Aug 15 '24	Proposed Sale	57.95	10,000	579,488		Aug 15 04:31 PM
Posard Matthew L.	Director	Aug 14 '24	Sale	57.70	9,881	570,134	69,874	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 13 '24	Sale	56.19	10,000	561,930	79,755	Aug 14 04:57 PM
Posard Matthew L.	Director	Aug 12 '24	Sale	55.72	10,000	557,230	89,755	Aug 14 04:57 PM
HELEN TORLEY	Officer	Aug 14 '24	Proposed Sale	57.25	10,000	572,472		Aug 14 04:08 PM
HELEN TORLEY	Officer	Aug 13 '24	Proposed Sale	56.25	10,000	562,496		Aug 13 04:19 PM
Posard Matthew L.	affiliate	Aug 13 '24	Proposed Sale	54.15	30,000	1,624,500		Aug 07 04:41 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Option Exercise	15.19	10,000	151,854	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Option Exercise	8.11	10,000	81,100	178,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 24 '24	Sale	55.12	10,000	551,150	168,176	Jul 24 05:48 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jul 23 '24	Sale	54.89	10,000	548,873	168,176	Jul 24 05:48 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Option Exercise	22.50	5,000	112,500	19,488	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jul 22 '24	Sale	53.93	5,000	269,662	15,480	Jul 23 04:37 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Option Exercise	22.50	10,000	225,000	25,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 28 '24	Sale	52.04	10,000	520,400	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 27 '24	Sale	51.93	10,000	519,340	15,480	Jun 28 04:06 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Jun 26 '24	Sale	51.82	10,000	518,200	15,480	Jun 28 04:06 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Option Exercise	8.11	10,000	81,100	178,176	Jun 20 04:17 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	Jun 18 '24	Sale	49.43	10,000	494,260	168,176	Jun 20 04:17 PM
Posard Matthew L.	Director	Jun 12 '24	Sale	50.62	10,000	506,190	99,755	Jun 13 04:15 PM
Posard Matthew L.	Director	Jun 11 '24	Sale	50.01	10,000	500,110	109,755	Jun 13 04:15 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Option Exercise	8.11	10,000	81,100	178,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 22 '24	Sale	45.38	10,000	453,840	168,176	May 22 05:24 PM
LaBarre Michael J.	SVP, CHIEF TECHNICAL OFFICER	May 21 '24	Sale	45.16	10,000	451,640	168,176	May 22 05:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HALO

Halozyme Therapeutics Inc

Upgrade your FINVIZ experience